SCHEMBL405771

SCHEMBL405771

CCOC(=O)Nc1ccc(C)c(F)c1C#N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
NLRP3 Q96P20 3/20 0.46
KCNQ3 O43525 5/20 0.45
KCNQ2 O43526 5/20 0.45
ALDH1A1 P00352 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HPGD P15428 1/20 0.43
LMNA P02545 1/20 0.42
KCNQ4 P56696 3/20 0.41
KCNQ5 Q9NR82 2/20 0.41
ABCB11 O95342 1/20 0.41
ESR1 P03372 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12225059 0.86 CYP1A2 (0.48) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL10287054 0.84 KCNQ2 (0.47) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL7503373 0.81 ALDH1A1 (0.52) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL28738833 0.80 ALDH1A1 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL22988070 0.75 NLRP3 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL29649042 0.75 ALDH1A1 (0.52) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL7507310 0.75 ALDH1A1 (0.68) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL22987403 0.75 ALDH1A1 (0.52) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL29649017 0.75 ALDH1A1 (0.68) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3
SCHEMBL22987877 0.75 NLRP3 (0.49) SMN1; SMN2CYP1A2CYP2C9CYP2C19NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 SMN1; SMN2 4774/4885CYP1A2 2609/4885CYP2C9 2484/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 SMN1; SMN2 4774/4885CYP1A2 2609/4885CYP2C9 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.